PD-L1 score (CPS) of 20 and above significantly increased the median OS from 7.3 to 14.6 months (p = 0.04) confirming the importance of PD-L1 score as a predictive factor for effect of pembrolizumab in head and neck cancer. The gene discussed is CD274; the disease is head and neck cancer.